Antoni Fernandez‐Oliva
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Antoni Fernandez‐Oliva has a total of 9 co-authors. Here are the top co-authors by number of shared publications:
Berta Serrano
Maternal Fetal Medicine Unit Department of Obstetrics Hospital Universitari Valld’Hebron Universitat Autònoma de Barcelona Barcelona Spain
1 shared publication- Carmen Garrido-Gimenez
Institut de Recerca Sant Pau (IR SANT PAU), Sant Quintí 77-79, 08041 Barcelona, Spain
1 shared publication Elena Carreras
Maternal Fetal Medicine Unit Department of Obstetrics Hospital Universitari Valld’Hebron Universitat Autònoma de Barcelona Barcelona Spain
1 shared publicationErika Bonacina
Maternal Fetal Medicine Unit Department of Obstetrics Hospital Universitari Valld’Hebron Universitat Autònoma de Barcelona Barcelona Spain
1 shared publicationHelena Tur
Maternal Fetal Medicine Unit Department of Obstetrics Hospital Universitari Valld’Hebron Universitat Autònoma de Barcelona Barcelona Spain
1 shared publication- Manel Mendoza
Maternal‐Fetal Medicine Research Group, Vall D'hebron Research Institute (VHIR), Vall D'hebron Barcelona Hospital Campus Centres de Recerca de Catalunya (CERCA) Barcelona Spain
1 shared publication
Latest Publications
- 29 August 2020
- Published by Wiley in Acta Obstetricia et Gynecologica Scandinavica
- Vol. 100 (1) , 119-128
Soluble fms‐like tyrosine kinase to placental growth factor ratio in different stages of early‐onset fetal growth restriction and small for gestational age
Introduction: Increased soluble fms‐like tyrosine kinase to placental growth factor ratio (sFlt‐1/PlGF) has been demonstrated in early‐onset fetal growth restriction (FGR) and small for gestational age (SGA). sFlt‐1/PlGF cut‐offs have been described to assess preeclampsia severity; however, sFlt‐1/PlGF values present in early‐onset SGA and different FGR severity stages remain unknown. Hence, the objective of this study was to describe and compare the sFlt‐1/PlGF values and pregnancy outcomes among early‐onset SGA/FGR stages.Material and methods: This is a prospective case‐control study conducted at Vall d’Hebron University Hospital. Singleton pregnancies with estimated fetal weight .05) and pregnancy outcomes. However, all FGR stages had significantly poorer outcomes and greater sFlt‐1/PlGF values than those of SGA and controls. Furthermore, median values differed significantly among all FGR severity stages (9.76 for stage I; 284.3 for stage II, and 625.02 for stage III, P < .05) increasing with FGR severity as well as the frequency of adverse pregnancy outcomes. Additionally, a significant correlation was found between greater sFlt‐1/PlGF ratio values and gestational age at delivery, time from diagnosis to delivery, birthweight z‐scores, and time in neonatal intensive care unit (r = −.637, r = −.576, r = −.161, and r = .311, respectively).Conclusions: Values of sFlt‐1/PlGF at diagnosis permit early‐onset FGR/SGA severity classification with good correlation with Doppler ultrasound findings and the occurrence of adverse outcomes. Thus, sFlt‐1/PlGF could aid in early‐onset FGR/SGA severity classification and clinical management when Doppler assessment is not feasible.
- 29 August 2020
- Published by Wiley in Acta Obstetricia et Gynecologica Scandinavica
- Vol. 100 (1) , 119-128
Soluble fms‐like tyrosine kinase to placental growth factor ratio in different stages of early‐onset fetal growth restriction and small for gestational age
Introduction: Increased soluble fms‐like tyrosine kinase to placental growth factor ratio (sFlt‐1/PlGF) has been demonstrated in early‐onset fetal growth restriction (FGR) and small for gestational age (SGA). sFlt‐1/PlGF cut‐offs have been described to assess preeclampsia severity; however, sFlt‐1/PlGF values present in early‐onset SGA and different FGR severity stages remain unknown. Hence, the objective of this study was to describe and compare the sFlt‐1/PlGF values and pregnancy outcomes among early‐onset SGA/FGR stages.Material and methods: This is a prospective case‐control study conducted at Vall d’Hebron University Hospital. Singleton pregnancies with estimated fetal weight .05) and pregnancy outcomes. However, all FGR stages had significantly poorer outcomes and greater sFlt‐1/PlGF values than those of SGA and controls. Furthermore, median values differed significantly among all FGR severity stages (9.76 for stage I; 284.3 for stage II, and 625.02 for stage III, P < .05) increasing with FGR severity as well as the frequency of adverse pregnancy outcomes. Additionally, a significant correlation was found between greater sFlt‐1/PlGF ratio values and gestational age at delivery, time from diagnosis to delivery, birthweight z‐scores, and time in neonatal intensive care unit (r = −.637, r = −.576, r = −.161, and r = .311, respectively).Conclusions: Values of sFlt‐1/PlGF at diagnosis permit early‐onset FGR/SGA severity classification with good correlation with Doppler ultrasound findings and the occurrence of adverse outcomes. Thus, sFlt‐1/PlGF could aid in early‐onset FGR/SGA severity classification and clinical management when Doppler assessment is not feasible.